目的 探討荊防顆粒聯(lián)合奧司他韋治療小兒流感的臨床療效。方法 選取2022年8月—2023月10月在蘇州市中西醫(yī)結(jié)合醫(yī)院診治的流行性感冒患兒111例，根據(jù)治療方案差異將患兒分成對照組（55例）和治療組（56例）。對照組患兒口服磷酸奧司他韋顆粒，體質(zhì)量≤15 kg，30 mg/次，15 kg＜體質(zhì)量≤23 kg，45 mg/次，23 kg＜體質(zhì)量≤40 kg，60 mg/次，＞40 kg患兒75 mg/次，2次/d。治療組在對照組治療基礎(chǔ)上口服荊防顆粒，年齡＜3歲者每次1/4袋，3歲≤年齡＜5歲者每次1/3袋，5歲≤年齡≤10歲者每次1/2袋，年齡＞10歲者1袋/次，3次/d。兩組患兒均進(jìn)行5 d的治療。觀察兩組患兒臨床療效，比較治療前后兩組患兒臨床癥狀消失時間，及血清炎癥因子超敏C反應(yīng)蛋白（hs-CRP）、血清淀粉樣蛋白A（SAA）和干擾素-γ（IFN-γ）水平。結(jié)果 治療后，對照組和治療組臨床總有效率分別為85.45%、96.43%，兩組比較差異具有統(tǒng)計學(xué)意義（P＜0.05）。治療后，治療組患兒發(fā)熱惡寒、周身酸痛、咳嗽流涕、咽痛等臨床癥狀消失時間均明顯早于對照組（P＜0.05）。治療后，兩組患兒血清炎癥因子hs-CRP、SAA、IFN-γ水平均較治療前顯著下降（P＜0.05），且治療后治療組炎癥因子水平均明顯低于對照組（P＜0.05）。結(jié)論 荊防顆粒聯(lián)合奧司他韋治療小兒流行性感冒的治療效果顯著，不僅能夠顯著改善患兒臨床癥狀，同時還能夠促進(jìn)體內(nèi)炎癥水平的修復(fù)。

Objective To explore the clinical efficacy of Jingfang Granules combined with oseltamivir in treatment of children with influenza. Methods Children (111 cases) with influenza in Suzhou Hospital of Integrated Traditional Chinese and Western Medicine from August 2022 to October 2023 were divided into control (55 cases) and treatment (56 cases) group based on different treatments. Children in the control group were po administered with Oseltamivir Phosphate Granules, body mass ≤15 kg, 30 mg/time, 15 kg < body mass ≤ 23 kg, 45 mg/time, 23 kg < body mass ≤ 40 kg, 60 mg/time, body mass > 40 kg, 75 mg/time, twice daily. Children in treatment group were po administered with Jingfang Granules on basis of control group, < 3 years old, 1/4 bag/time, 3 years ≤ age < 5 years, 1/3 bag/time, 5 years ≤ age ≤ 10 years, 1/2 bag/time, > 10 years, 1 bag/time, 3 times daily. Children in two groups were treated for 5 d. After treatment, the clinical evaluations were evaluated, the disappearance time of clinical symptoms, the levels of serum hs-CRP, SAA and IFN-γ in two groups before and after treatment were compared. Results After treatment, the total clinical effective rates in the control group and the treatment group were 85.45% and 96.43%, respectively, and the difference between the two groups was statistically significant (P < 0.05). After treatment, the disappearance time of clinical symptoms such as fever and aversion to cold, body aches, coughing and runny nose, and sore throat in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the levels of serum inflammatory factors hs-CRP, SAA, and IFN-γ in two groups were significantly decreased compared with those before treatment (P < 0.05), and the levels of inflammatory factors in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Jingfang Granule combined with oseltamivir has a significant therapeutic effect on children with influenza. It can not only significantly improve the clinical symptoms of children, but also promote the repair of the level of inflammation.

R974;R985